Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 January 2019 | Story Zama Feni | Photo Barend Nagel
Prof Matlabisa
Prof Motlalepula Matlabisa of the Department of Pharmacology.

Two South African government departments have granted the University of the Free State’s Department of Pharmacology a combined amount of R15 million for the establishment of four tea farms in the disadvantaged communities in the North West and Eastern Cape Communities.

The head of the project Prof Motlalepula Matsabisa at the Department of Pharmacology said that that Department of Environmental Affairs (DEA) has granted an amount of R10 million for the community research in the respective provinces.

This grant is a top up to the R5 million they received from the Department of Science and Technology for the “community implementation on indigenous health infusions or teas as commonly known.”

The DEA will in the near future sign a Memorandum of Agreement (MOA) with the university.


Tea project set to empower communities


“The project is to implement and build structures in the four communities we work with in the North West and Eastern Cape,” he said.

The identified areas for the project are in the Eastern Cape towns of Alice and Idutywa as well another two North West communities in Zeerust.

Prof Matsabisa indicated that the project will be a manifestation of “how science can contribute to economic growth, poverty alleviation and job creation.” 

“It was very interesting to have discovered that some French and German companies have already displayed interest in the projects,” he said.

He stated that a project of this nature is a good initiative by the UFS and it will also show that the university’s research activities are national. “We have been researching and developing indigenous teas which have now attracted interest locally and internationally by huge companies such as Nestle, Tiger Brands, Moringa World etc,” he said. 


Taking it slowly


At the initial stages of the tea farming project, Prof Matsabisa said they would start in small portions of utilising five hectares in each of the four projects and as the project gains momentum, they would expand.

Prof Matlabisa said that an environmental impact assessment has already been conducted and they were waiting for the DEA to give them a go ahead for the land preparations.



News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept